A novel hypocrellin-based assembly for sonodynamic therapy against glioblastoma-Reference-Cited by-同舟云学术

A novel hypocrellin-based assembly for sonodynamic therapy against glioblastoma

Published:2022 Issue:1 Volume:10 Page:57-63
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Zhang Chuangli¹,Wu Jiasheng¹,Liu Weimin¹²^ORCID,Zheng Xiuli¹^ORCID,Zhang Wenjun³^ORCID,Lee Chun-Sing³^ORCID,Wang Pengfei¹²^ORCID

Affiliation:

1. Key Laboratory of Photochemical Conversion and Optoelectronic Materials and CityU-CAS Joint Laboratory of Functional Materials and Devices, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China

2. University of Chinese Academy of Sciences, Beijing 100049, P. R. China

3. Center of Super-Diamond and Advanced Films (COSDAF) & Department of Materials Science and Engineering, City University of Hong Kong, Kowloon 999077, Hong Kong SAR, People's Republic of China

Abstract

A cysteamine and tryptophan-modified hypocrellin derivative was synthesized and a novel hypocrellin-based assembly was prepared. This assembly could be used as an effective sonosensitizer for sonodynamic therapy against glioblastoma.

Funder

National Natural Science Foundation of China

Beijing Municipal Science and Technology Commission

Chinese Academy of Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2022/TB/D1TB01886H

Reference57 articles.

1. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma